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suitable control strains and the use of conventional
identification technology.
Despite the numerous studies claiming good results with
probiotics, more well-designed studies are required in humans
to substantiate earlier findings.  In a recent critical evaluation
of pre- and probiotics, Roberfroid indicated that, based on the
strength of available evidence, a strong case could be made for
the use of probiotics in lactose intolerance and that the
scientific status of immunostimulation, faecal mutagenesis and
colonic microflora is at this time still preliminary and should be
investigated further in human subjects.6 Prebiotics in their own
right may also confer benefit and their role in promoting
calcium bioavailability is promising.6 More human trials are
required to validate the many potential benefits of pre- and
probiotics.
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Expanding access to antiretroviral therapy through the
public sector — the challenge of retaining patients in 
long-term primary care
The growing movement to make antiretroviral therapy (ART)
widely available in South Africa has spurred discussion on
different aspects of delivering HIV treatment services,1 2
deliberations that have taken on new importance in light of the
national government’s recent announcement of a plan to make
ART widely available in the public sector. Yet one critical
aspect of delivering ART effectively within HIV care services
has received surprisingly little attention, namely the challenge
of retaining patients in long-term programmes of primary care.
Here we discuss the importance of distinguishing adherence to
medications from retention in care, as well as the possible
interventions that may be employed to improve long-term
patient retention. 
Adherence with antiretroviral medications is critical in
achieving favourable clinical outcomes and preventing HIV
resistance.3 While the basic notion that patients must be
retained in care in order to adhere to their treatment regimens
may seem obvious, it has been overlooked in many studies of
ART adherence to date. For instance, one recent publication of
medication adherence patterns among clinical trial patients in
Cape Town found that 16% of participants dropped out of
treatment within 2 years. But rather than being considered
non-adherent after they dropped out (because they could no
longer access ART), these patients were either excluded from
adherence analysis, or analysed according to the results of their
last pill count before leaving the study. This approach, which
has been used by other authors as well, is likely to
overestimate the actual adherence of patients initiating
treatment, suggesting that the relationship between adherence
to treatment and retention in care requires clarification.
Adherence to treatment typically focuses on patients’ pill-
taking behaviours, and usually on the proximal factors (such as
knowledge of treatment and its side-effects, barriers and
attitudinal issues) which can be addressed through counselling
interventions.5 In contrast, retention in care is a broader concept
that emphasises attending regularly scheduled clinical
appointments and making modifications in lifestyle needed for
effective chronic disease management.6 A patient’s retention in
HIV care is a necessary precursor to his or her adherence to
HIV therapy, but adherence with clinic visits and care does not
necessary imply adherence with medications. Moreover,
adherence to care for HIV-infected individuals not yet eligible
for ART may be associated with substantial benefits, for
instance receipt of psychosocial support or prophylaxis against
opportunistic infections. 
Retention in care of patients with chronic diseases,
particularly when asymptomatic, is a longstanding challenge to
health care systems. Most local experiences of retaining
patients in HIV treatment programmes come from well-
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resourced, small-scale service or research projects,7-9 and it is
unclear how these experiences will relate to large-scale and
resource-constrained public sector treatment programmes.
Useful insights may be drawn from the experience of other
public sector primary care services. For instance, during 2002
the completion rate for tuberculosis treatment among new
smear-positive cases ranged across provinces from 52% to
74%.10 In hypertension management programmes, available
estimates of the proportion of patients retained and managed
successfully over the short term are approximately two-
thirds,11,12 somewhat better than the widely recognised ‘rule of
halves’ in which only half of individuals with documented
hypertension are treated effectively.13 If these figures can be
extrapolated to future large-scale public sector HIV treatment
programmes, then perhaps we may optimistically anticipate
levels of retention in ART services at 60 - 80% per year. By
definition, patients who are not retained in care cannot adhere
to therapy, placing probable levels of medication adherence
somewhere below this level — and substantially lower than the
estimates predicted by research studies. 
Pilot programmes across South Africa and elsewhere have
developed various strategies to help ensure patient retention in
care over the long term. Many programmes utilise social
and/or behavioural eligibility criteria in an attempt to restrict
access to treatment to those patients thought most likely to be
retained in care. This may involve limiting enrolment to
patients who have demonstrated the ability to attend regular
clinical appointments during a preparatory phase, those who
have disclosed their HIV status, and/or those who have easy
access to the health care facility.7 However, there is evidence
that providers have limited success in predicting adherence
prospectively,14 and such selection processes may be
problematic in public sector programmes that seek to make
ART widely available. In the long run, identifying and
addressing the major barriers to retention in care may be more
fruitful than attempting to exclude patients facing such
barriers. Another common measure to ensure patient retention
in HIV treatment programmes involves tracing patients who
have missed an appointment to their homes. Yet given the
large number of patients and limited resources facing public
sector services, it will be more efficient to prevent missed
appointments than to spend staff resources tracking those who
have already missed visits. 
HIV treatment programmes may also be designed using
specific structural elements that help facilitate patient retention.
Comprehensive services that emphasise clinical care across the
spectrum of HIV disease, rather than simply providing ART to
relatively ill patients, will help to orient patients to the habit of
attending regularly scheduled appointments before they
initiate ART. Programmes that integrate the delivery of clinical
care with non-clinical support services, such as psychosocial
support, nutritional interventions, and/or income generation,
can help to address the social and contextual barriers to long-
term care that many patients will face. Importantly, HIV
treatment programmes that are family-oriented, and that are
able to provide care to families and households rather than
discrete individuals, will help to take advantage of patients’
social contexts to ensure long-term retention in care. Over the
past decade, HIV treatment programmes in the developed
world have struggled to find interventions that can create a
strong social network to support patients in long-term care.15
Services that provide integrated care to women, men and their
children (recognising the complexities of defining ‘families’ in
many instances) can begin to take advantage of existing social
support networks. Such family-oriented treatment programmes
may help to increase the likelihood that patients continue to
attend appointments and receive services, in turn improving
drug adherence and clinical outcomes. 
This is by no means a comprehensive list of all the steps that
may be taken to help patients remain in HIV primary care over
the long term, and there are likely to be other, locally adapted
and creative approaches to ensuring high rates of retention in
care.6,16 Recognising the separate but related challenges of first
retaining patients in care programmes, and then having
patients adhere to their drug regimens, may make a critical
contribution to the long-term impact of HIV treatment services
in the public sector.
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